Silencing of CCL5 in TAMs inhibits bone metastasis and self‐renewal of PCSCs in vivo and therefore TAMs/CCL5 can be a novel target in predicting prognosis of prostate cancer and inhibiting metastasis.138. This evidence concerns the gene CCL5 and prostate carcinoma.